AspenBio Pharma to Present at the Noble Financial Equity Conference
CASTLE ROCK, CO--(Marketwire - August 11, 2008) - AspenBio Pharma, Inc. (NASDAQ: APPY) an
emerging bio-pharmaceutical company dedicated to the development of novel
drugs and diagnostics for animals and humans, has been invited to present
at the Fourth Annual Noble Financial Equity Conference to be held August
18-19 at the Loews Lake Las Vegas Resort, Nevada.
AspenBio president and CEO, Richard G. Donnelly, is scheduled to present on
Monday, August 18 at 12:30 p.m. Pacific Time. The presentation will be
webcast LIVE featuring high-definition, streaming video and PowerPoint
slides. Access is available by logging on to the conference website
www.noblemadmax.com or by using the following link:
http://hosted.mediasite.com/hosted4/Viewer/?peid=0c0c799c-d64a-403b-912a-31891ddb9f5b. It is recommended that interested parties register at least
15 minutes prior to the start of the presentation to ensure timely access.
Mr. Donnelly will discuss the continued advancement of AppyScore™, the
world's first blood-based screening/triage test for human appendicitis. The
company is conducting an 800 patient FDA clinical trial in preparation for
a late 2008 FDA 510(k) filing. He will also discuss the exclusive license
and commercialization agreement AspenBio recently signed with Novartis
Animal Health, Inc. for the development and worldwide launch of AspenBio's
novel bovine reproduction drugs, BoviPure LH™ and BoviPure FSH™.
About Noble Financial
Noble Financial is a privately held, full-service capital markets firm
driven by what is often overlooked by other firms -- uncovering the value
embedded in the orphaned, undiscovered or misunderstood company. The
company focuses on converting market inefficiencies into profit
opportunities. Noble Financial supports emerging companies through
strategic advice, investment banking, market-making, sales & trading,
comprehensive equity research, and the development of institutional
support. Noble Financial's equity conferences -- 2008 marks their fourth
annual -- allow for a unique blend of professional and personal interaction
among a diverse cross-section of executives. The company has operated for
24 years and has offices in Florida, New York City and Boston.
About AspenBio Pharma, Inc.
AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the
discovery; development, manufacture, and marketing of novel proprietary
products, including those that enhance the reproductive efficiency of
animals and that have large worldwide market potential. The company was
originally formed to produce purified proteins for diagnostic applications
and has become a leading supplier of human hormones to many of the nation's
largest medical diagnostic companies and research institutions. The company
has successfully leveraged this foundational science and technology
expertise to rapidly develop an enviable late-stage pipeline of several
novel reproduction hormone analogs for wide-ranging therapeutic use in
animals of economic importance. AspenBio Pharma continues to advance the
development and testing of its two first-generation blood-based human
diagnostic tests designed to rapidly help diagnose or rule out acute
appendicitis in patients complaining of abdominal pain. For more
information, go to www.aspenbiopharma.com.
Forward-Looking Statements
This news release includes "forward-looking statements" of AspenBio Pharma,
Inc. ("APPY") as defined by the Securities and Exchange Commission (the
"SEC"). All statements, other than statements of historical fact, included
in the press release that address activities, events or developments that
APPY believes or anticipates will or may occur in the future are
forward-looking statements. These statements are based on certain
assumptions made based on experience, expected future developments and
other factors APPY believes are appropriate in the circumstances. Such
statements are subject to a number of assumptions, risks and uncertainties,
many of which are beyond the control of APPY. Investors are cautioned that
any such statements are not guarantees of future performance. Actual
results or developments may differ materially from those projected in the
forward-looking statements as a result of many factors, including
statements regarding the ability to successfully complete the development
of, obtain FDA approval for, cost effectively manufacture and generate
revenues from the appendicitis test as well as the animal products under
this agreement and other new products, execute agreements required to
successfully advance the company's objectives, retain the scientific
management team to advance the products, overcome adverse changes in market
conditions and the regulatory environment, fluctuations in sales volumes,
obtain and enforce intellectual property rights, and realization of
intangible assets. Furthermore, APPY does not intend (and is not obligated)
to update publicly any forward-looking statements. The contents of this
news release should be considered in conjunction with the warnings and
cautionary statements contained in APPY's recent filings with the SEC.